Overview

* Bioceres fiscal Q1 revenue declines 17% yr/yr, missing analyst expectations

* Adjusted EBITDA for fiscal Q1 rises 61%, beating analyst expectations

* Company focuses on margin expansion and cost discipline amid revenue decline

Outlook

* Company prioritizes strengthening capital structure and financial flexibility

Result Drivers

* REVENUE DECLINE - Co attributes 17% revenue decline to strategic shift away from low-margin sales and timing issues in Latam markets

* MARGIN EXPANSION - Gross margin increased from 40% to 47% due to a more profitable product mix

* WORKING CAPITAL IMPROVEMENT - Co reports improved working capital efficiency despite seasonally high needs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Miss $77.50 $90.23

Revenue mln mln (4

Analysts

)

Q1 Beat $13.60 $11.02

Adjusted mln mln (3

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the agricultural chemicals peer group is "buy."

* Wall Street's median 12-month price target for Bioceres Crop Solutions Corp ( BIOX ) is $5.00, about 61.4% above its November 11 closing price of $1.93

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)